Busulfan

Generic Name: Busulfan

Brand Names: Busulfex, Myleran, Busulfan Fresenius Kabi

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄O_₆S_₂

CAS Number: 55-98-1

Unique Ingredient Identifier: G1LN9045DK

Background: Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...

Indication: For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...

Associated Conditions: Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia in Remission

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: ATG
Drug: Clofarabine

First Posted Date: 2023-06-23

Last Posted Date: 2023-11-15

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 302

Registration Number: NCT05917405

Locations: 🇫🇷
CRLC Caen, Caen, France
🇫🇷
CHU Limoges, Limoges, France
🇫🇷
CHU Besançon, Besançon, France

and more 20 locations

The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

Phase 3

Not yet recruiting

Conditions: Thrombotic Disorder

Interventions: Drug: Busulfan
Drug: N-acetyl-cysteine
Drug: Cyclophosphamide
Drug: Cytarabine

First Posted Date: 2023-06-18

Last Posted Date: 2023-06-18

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 260

Registration Number: NCT05907486

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2

Recruiting

Conditions: Hematologic Malignancy
Minimal Residual Disease
PTPN11 Gene Mutation
Monosomy 7
Chromosome Abnormality
Acute Leukemia
Remission
TP53
Intrachromosomal Amplification of Chromosome 21
Myelodysplasia

Interventions: Drug: Fludarabine
Drug: Rituximab
Drug: Busulfan
Drug: Melphalan
Drug: Levetiracetam

First Posted Date: 2023-02-21

Last Posted Date: 2024-10-21

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 150

Registration Number: NCT05735717

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Phase 2

Suspended

Conditions: Graft Vs Host Disease
Graft-versus-host-disease
Myelodysplastic Syndromes

Interventions: Drug: Busulfan
Drug: Melphalan
Drug: Fludarabine
Device: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)

First Posted Date: 2022-11-15

Last Posted Date: 2024-11-25

Lead Sponsor: Guenther Koehne

Target Recruit Count: 50

Registration Number: NCT05617625

Locations: 🇺🇸
Miami Cancer Institute, Miami, Florida, United States

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Phase 2

Terminated

Conditions: Myeloid Malignancy
Hematologic Malignancy

Interventions: Drug: Ruxolitinib
Drug: Anti-thymocyte globulin (ATG)
Drug: Mesna
Drug: Cyclosporine
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Methotrexate
Radiation: Total Body Irradiation (radiation treatment)
Drug: Busulfan
Drug: Bone marrow infusion
Drug: Thiotepa

First Posted Date: 2022-10-14

Last Posted Date: 2024-07-10

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 3

Registration Number: NCT05579769

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Pediatric Cancer

Interventions: Drug: Uproleselan
Drug: Fludarabine
Drug: Clofarabine
Drug: Busulfan

First Posted Date: 2022-10-06

Last Posted Date: 2024-08-19

Lead Sponsor: Malika Kapadia

Target Recruit Count: 1

Registration Number: NCT05569512

Locations: 🇺🇸
Helen DeVos Children's Hospital/Spectrum Health, Grand Rapids, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

CD34+ Transplants for Leukemia and Lymphoma

Phase 2

Not yet recruiting

Conditions: Leukemia, Lymphocytic, Acute
Leukemia, Myeloid, Acute

Interventions: Radiation: Total Body Irradiation (TBI)
Drug: Busulfan
Drug: Thiotepa
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-10-04

Last Posted Date: 2024-11-25

Lead Sponsor: Guenther Koehne

Target Recruit Count: 100

Registration Number: NCT05565105

Locations: 🇺🇸
Baptist Health South Florida/Miami Cancer Institute, Miami, Florida, United States

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Phase 3

Recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell

Interventions: Drug: Chidamide
Drug: Carmustine
Drug: Cladribine
Drug: Etoposide
Drug: Gemcitabine
Drug: Cytarabine
Drug: Busulfan
Drug: Melphalan
Procedure: Autologous hematopoietic stem cell transplant

First Posted Date: 2022-07-20

Last Posted Date: 2022-07-25

Lead Sponsor: Sichuan University

Target Recruit Count: 306

Registration Number: NCT05466318

Locations: 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳
People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China

and more 8 locations

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease

Interventions: Drug: Sirolimus
Drug: Cyclophosphamide
Drug: Alemtuzumab
Drug: Busulfan
Biological: Pheripheral blood stem cells
Drug: Tociluzumab
Drug: Emapalumab-Izsg
Drug: Total Body Irradiation

First Posted Date: 2022-07-18

Last Posted Date: 2024-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT05463133

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

First Posted Date: 2022-07-14

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 435

Registration Number: NCT05457556

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 59 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy